Indoco Remedies Reports Significant Financial Declines, Highlighting Operational Challenges in March 2025

Indoco Remedies, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a challenging period for the company, with several key metrics reflecting significant declines compared to previous quarters.
The company's operating profit to interest ratio has reached its lowest point at -0.04 times, highlighting difficulties in managing interest payments. Additionally, the profit before tax less other income (PBT) has shown a notable decline, recorded at Rs -47.54 crore, which is substantially lower than the average of the previous four quarters. Similarly, the profit after tax (PAT) stands at Rs -40.39 crore, also reflecting a significant drop from historical averages.

Net sales have decreased to Rs 390.21 crore, marking the lowest figure in the last five quarters and indicating a negative trend in sales performance. Furthermore, the operating profit margin has fallen to -0.20%, suggesting a decline in operational efficiency. The earnings per share (EPS) have also reached a low of Rs -4.38, indicating reduced profitability for shareholders.

In light of these results, Indoco Remedies has experienced an adjustment in its evaluation, with its score reflecting these underlying trends.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.